New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
|Articles|October 10, 2011
Supplements and Featured Publications
- The Case for Early Initiation of Monotherapies and Delayed Dopaminergic Therapy in Parkinson's Disea
- Volume 17
- Issue 12 Suppl
The Case for Early Initiation of Monotherapies and Delayed Dopaminergic Therapy in Parkinson's Disease
Advertisement
After reading "The Case for Early Initiation of Monotherapies and Delayed Dopaminergic Therapy in Parkinson’s Disease,” participants must complete the online evaluation form and achieve a passing score of 70% or higher on the online posttest. Upon submission of the completed evaluation and posttest, participants may print their statement of credit.
Articles in this issue
Advertisement
Related to this article
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
Simple operational changes are proving more effective at closing gaps in cardiovascular-kidney-metabolic (CKM) syndrome care than education campaigns alone, according to panelists at at Population Health Roundtable
Panelists at AJMC roundtables in Philadelphia, Boston, Washington, DC, and Chicago traced why atopic dermatitis stays undertreated despite new therapies.
Eye care access for underserved patients with diabetes is limited and poorly understood. We identified barriers and innovative solutions to improve overall care and establish evidence-based practices.
Patient understanding should be treated as a measurable equity outcome, not an assumed byproduct of care.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
3
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
4
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
5